Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 4, 1997, Pages 361-369

  Keung, Anther C F ^a   Landriault, Hélène ^c   Lefebvre, Marc ^e   Gossard, Denis ^b   Dempsey, Ellen E ^c   Juneau, Martin ^d   Dimmitt, Dan ^a   Castles, Mark ^a   Roberts, Lisa ^a   Spénard, Jean ^e  

^a SANOFI   (France)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c Hoechst Marion Roussel Canada R   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e NONE

Author keywords

dolasetron; intravenous; oral; pharmacokinetics; women

Indexed keywords

DOLASETRON MESILATE; DRUG METABOLITE; HYDRODOLASETRON; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; CROSS-OVER STUDIES; FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; QUINOLIZINES; SEROTONIN ANTAGONISTS; SEX FACTORS;

EID: 0030965072     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199705)18:4<361::AID-BDD25>3.0.CO;2-I     Document Type: Article

References (13)

1. Y. Merrouche, G. Catimel, P. Rebattu, A. Dumortier, J. P. Guastalla, P. O'Grady and M. Clavel, A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann. Oncol., 5, 549-551 (1994).
2. K. G. Kris, S. M. Grunberg, R. J. Gralla, L. Baltzer, S. A. Zaretsky, D. Lifsey, L. B., Tyson, L. Schmidt and W. F. Hahne, Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J. Clin. Oncol., 12, 1045-1049 (1994).
3. T. Conroy, P. Cappelaere, M. Fabbro, A. A. Fauser, T. A. Splinter, M. Spielmann, M. Schneider, B. Chevallier, A. Goupil, J. Chauvergne, Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. Am. J. Clin. Oncol., 17, 97-102 (1994).
4. H. Boxenbaum, T. Gillespie, K. Heck and W. Hahne, Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm. Drug Disposit., 13, 693-701 (1992).
5. 3 receptor antagonist. Drug Metab. Disposit., 23, 806-812 (1995).
6. H. Boxenbaum, T. Gillespie, K. Heck and W. Hahne, Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm. Drug Disposit., 14, 131-141 (1993).
7. J. F. Pritchard, J. C. Bryson, A. E. Kernodle, T. L. Benedetti and J. R. Powell, Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin. Pharmacol. Ther., 51, 51-55 (1992).
8. J. C. Bennett, Inclusion of women in clinical trials - policies for population subgroups. New Engl. J. Med., 329, 28-292 (1993).
9. R. B. Merkatz, R. Temple, S. Sobel, K. Feiden and D. A. Kessler, Women in clinical trials of new drugs. A change in Food and Drug Administration policy. New Engl. J. Med., 329, 292-296 (1993).
10. T. L. Hunt, M. Cramer, A. Shah, W. Stewart, C. R. Benedict and W. F. Hahne, A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J. Clin. Pharmacol., 35, 705-712 (1995).
11. Y. S. Choo, D. C. Dimmitt, J. S. McElvain, M. A. Castles, T. Arumugham, V. J. Vandiver, V. O. Bhargava, M. G. Eller, W. F. Hahne and S. J. Weir, Pharmacokinetics and dose proportionality of dolasetron mesylate following iv administration to healthy volunteers. Pharm. Res., 12, S388 (1995).
12. Y. S. Choo, D. C. Dimmitt, L. Martin, L. Meyerson and T. Arumugham, Hoechst Marion Roussel. Project report number S-94-0734-CDS. Research Report MCPR0080. Data on file (1994).
13. A. Shah, R. Lanman, V. Bhargava, S. Weir and W. Hahne, Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharm. Drug Disposit., 16, 177-189 (1995).